SCHEMBL11943581

SCHEMBL11943581

CCOCCCNc1c(N2CCN(C(=O)CCN)CC2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.46
DCTPP1 Q9H773 3/20 0.46
RXFP1 Q9HBX9 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.42
MAPT P10636 4/20 0.42
LMNA P02545 3/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR1A P08908 1/20 0.39
HTR7 P34969 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943590 0.94 ALDH1A1 (0.47) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL11943588 0.89 ALDH1A1 (0.49) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL11943258 0.88 ALDH1A1 (0.45) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL11943540 0.88 ALDH1A1 (0.45) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL11943584 0.87 ALDH1A1 (0.46) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL14080974 0.87 ALDH1A1 (0.44) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL14899775 0.86 SIGMAR1 (0.46) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL11943248 0.85 ALDH1A1 (0.46) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL11943583 0.85 ALDH1A1 (0.47) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT
SCHEMBL13304479 0.85 SMN1; SMN2 (0.55) ALDH1A1DCTPP1RXFP1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885DCTPP1 625/4885RXFP1 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.